BullFrog AI secures deal with top 5 pharma company, raises capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Wall Street ends down as US-Iran peace optimism fades
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
April 13, 2026 7:30 AM EDTGAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine learning to turn complex biomedical data into actionable insights, today issued the following letter to shareholders from Vin Singh, Founder and CEO:
Dear Fellow Shareholders,
BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations. We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late 2027, and are... More
